



# **AFRICAN WOMEN**

## **Prevention Community**

# **Accountability Board**

**LAUNCH: HIV Prevention Choice Manifesto for  
Women and Girls in Africa.**


**8th September 2023**

**Kampala, Uganda**

# AWPCAB Members:

12 Women, 6 Countries





Who we are  
What we do

**Geography:** Eastern &  
Southern Africa

**Focus:** Choice Agenda  
access and rollout

**Intergenerational  
Young women and  
Girls included**

**POLICY CHANGE:  
&  
FINANCING FOR  
CHOICE**

**Engagements:**  
National, Regional,  
and Global Levels



# Structure

- **Secretariat** : APHA (SA) & ICWEA (EA)
- **Communication**: WACI Health
- **Membership**
  - ✓ AWPCAB Members
  - ✓ Girls and Young Women
  - ✓ Key community organizations

# History

- 2010 till: Advocating for Contraceptive Options and choices – the first Global CAB, ECHO trial and options and choice agenda in the ECHO Trial and recommendations
- 2016 Dec: HPTN 084 consultation and pre-meeting with advocates on trial design and plans
- 2017: Aug: HPTN 084 consultation to review the study plans and build partnerships
- 2018: Advocates tracked the trial hold on HPTN 084 following data on NTD related to DTG, which is in the same class of drugs as CAB
- 2019: Advocates continue to follow the enrollment and conduct of trials
- 2020
  - March: HPTN publishes and presents trial data, noting the presence of ‘masked infections’ and testing considerations. Advocates break down trial results (e.g. conferences sessions, webinars, materials and briefs, etc.)
  - May: HPTN 083 early efficacy data
  - Mid to late-2020: Planned communications & advocacy around result scenarios for HPTN 084 results, ensuring options for women remain a priority; engaged in consultations /webinars around key issues; updated materials
  - November: HPTN 084 early efficacy data
- 2021: Advocates prepare for introduction of CAB for PrEP; other projects (BioPIC, MOSAIC, ViiV) focused on introduction kick into high gear
- WHO/AVAC Think Tanks on implementation studies and HIV testing, with active participation of advocates

# History Cont'd

2022

- March: Advocates participate in WHO Guideline Development Group, and release statements with demands around cost and manufacturing
- March/April: ViiV meets with African women's health advocates in South Africa, leading to the establishment of the African Women Community Prevention Accountability Board and subsequent bi-monthly meetings
- May: Workshops, think tanks (e.g. BioPIC), and consultations continue with CS
- June: Advocates meet with UNAIDS to discuss the choice agenda; publication of Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP; HPTN meeting with updates on OLE
- July: ViiV/KP Advisory Group consultation; AIDS 2022: launch of Coalition to Accelerate Access to Long-Acting PrEP, and announcement of voluntary license between MPP/ViiV, data from 083 (TG populations) and 084; Meeting with UNAIDS, PEPFAR
- Aug - Dec: CS involvement and leadership in implementation studies (linked with MOSAIC), BioPIC think tanks, CAB for PrEP Teach-in series, Coalition to Accelerate Access to Long-Acting PrEP CS caucus, AfroCAB working groups, etc.
- Continuous engagement with IPM

# History Cont'd

2023

Jan/Feb: Advocates await updates from MPP on selection of generics while continuing to engage with ViiV, provide input into implementation studies, and engage with national governments around registration for and rollout of CAB for PrEP

Feb: Preliminary findings that show protective levels with quarterly injections are presented at CROI



# What we do


- Mentoring young women and girls in East & Southern Africa
- Prioritizing Choice Advocacy
- Engaging in advocacy at national, regional, and global levels.
- Engagement with regulatory authorities
- Advocating for financing for choice
- Advocating with regulatory authorities



# Advocacy Moments



# Advocacy Moments






# Achievements

- ✓ UNAIDS: Gaining support from the UNAIDS Executive Director;
- ✓ Meeting with Amb. John Nkengsong leading to summoning his scientific Committee with clear and strong recommendations;
- ✓ Meeting with the EMA leading to their recommendation that the ring had a space within the prevention options;
- ✓ A champion for choice and manifesto.
- ✓ Advocating for funding from PEPFAR and Global Fund for DapiRing & Cab La;
- ✓ Active involvement in the 2022 AIDS Conference;
- ✓ Driving and sustaining advocacy efforts on choice for women and girls in Africa;
- ✓ Advocating for financing and inclusion of CHOICE programmes and language in Global Fund applications and PEPFAR;
- ✓ Conceptualization and drafting of the HIV prevention Choice Manifesto for women and girls in Africa;
- ✓ Manifesto Readiness: Ready to launch the manifesto;
- ✓ PEPFAR's funding the MOSAIC demonstration studies could be the nail to unlock the puzzle
- ✓ **The Global Fund commitment to fund DVR is a game changer**
- ✓ **LAUNCH OF THE CHOICE MANIFESTO**



# Collaborations For product introduction

- ViiV
  - Gilead
  - IPM
  - World Health Organization (WHO)
  - National regulatory authorities
  - National Governments (HIV prevention councils)
  - Communities
- 

# Meetings:

- Meetings with Ambassador Dr. John N. Nkengasong
- Meetings with the UNAIDS Executive Director
- Presentation at SAB
- Meetings with Global Fund
- Meetings with ViiV
- Attendance of meetings by WHO
- Local and community engagements in Country
- Two consultative meetings were held – one in Johannesburg (28th and 29th June 2022; and the last one in Montreal (29th July 2022) on the sides of the AIDS 2022 Conference.

# Products:

- HIV prevention Choice Manifesto for women and Girls in Africa:
- Multiple impacts on social media campaigns



# Challenges

- Translating Commitment into Actions
- Mobilization of Women and Partners
- Ambassador's Commitment and Actions
- Review and Input into the Manifesto
- Advocacy for Product Approvals with regulatory authorities



# Opportunities

- Building African women's leadership
- Setting the Agenda for HIV prevention centering choice





# Conclusion:

- Achieving the AGYW Prevention Agenda
- Continual Advocacy and Mobilization
- Collaboration and Commitment for Women's Health



CHOICE IN  
REAL  
WORLD

















# Acknowledgments

AWPCAB members

Governments & ADPs

UNAIDS

CASPR/AVAC

Aidsfonds

Women & Girls

